Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus OMNIPAQUE 210.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus OMNIPAQUE 210.
CHOLOGRAFIN SODIUM vs OMNIPAQUE 210
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodipamide (cholografin sodium) is a radiographic contrast agent that opacifies the biliary ducts and gallbladder by being excreted into bile via the hepatic organic anion transporter (OATP) and then concentrated in the gallbladder. It absorbs X-rays due to its iodine content, allowing visualization of the biliary tree.
Radiopaque contrast agent that contains iodine, which attenuates X-rays and provides radiographic visualization of vascular structures and organs. It does not have a pharmacological mechanism of action.
2-3 mL of 30% solution intravenously over 1-2 minutes, repeated if necessary up to a total of 10 mL.
Intravascular administration: 50-150 mL (10-30 g iodine) as bolus or infusion, based on procedure (CT, angiography, urography). Intravenous infusion for CT: 100-200 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In severe renal impairment (CrCl < 30 mL/min), half-life may extend to 10-20 hours, requiring dose adjustment.
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases). In neonates, half-life is 6-12 hours due to immature renal function.
Primarily renal excretion via glomerular filtration and tubular secretion. Approximately 70-80% of the dose is excreted unchanged in urine within 24 hours. Biliary excretion accounts for less than 10%, with fecal elimination minimal.
Renal: ~95% unchanged within 24 hours via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent